Overview
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for energy metabolism, DNA repair and the activity of sirtuins — the longevity proteins. Its levels decline roughly 50% between youth and middle age, and restoring them is one of the central bets of modern longevity science.
The market offers NAD+ itself (IV drips, injections) and oral precursors (NMN, NR) that the body converts into NAD+.
How It Works
NAD+ shuttles electrons in mitochondrial energy production — without it, cells cannot make ATP. It is also consumed by enzymes like sirtuins and PARPs that regulate aging, DNA repair and inflammation. Declining NAD+ means both less energy and less repair capacity.
The delivery problem
Oral NAD+ is largely degraded in digestion, which is why clinics use IV infusions and why the precursor strategy (NMN, NR) became popular — these smaller molecules survive absorption and are converted to NAD+ inside cells. Human trials confirm precursors reliably raise blood NAD+ levels.
Key Benefits
Cellular energy — restoring NAD+ improves mitochondrial function in animal models of aging.
DNA repair capacity — PARP enzymes depend on NAD+; deficiency impairs repair.
Sirtuin activation — the longevity pathway that made NAD+ famous.
Subjective energy and clarity — the most reported effects from IV clinics, though placebo-controlled data is thin.
Side Effects & Considerations
IV NAD+ infusions commonly cause flushing, chest pressure, nausea and cramping during administration — rate-dependent and unpleasant but not dangerous. Oral precursors are well tolerated at studied doses.
The honest state of the science
Raising NAD+ in humans is proven; proving that doing so extends healthspan or lifespan is not. The animal data is spectacular, the human outcome data is early. IV NAD+ is expensive, uncomfortable and lacks trial support for most clinic claims; oral precursors are cheaper, easier and better studied for raising levels. A reasonable longevity bet — but a bet, not a fact.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Oral precursors (evidence-based) | NR 300-1000 mg or NMN 250-500 mg | Daily | Ongoing | The route with human trial data for raising NAD+ levels. |
| IV infusion (clinic) | 250-1000 mg | Per clinic protocol | Sessions of 2-4 hours | Slow infusion rate is essential to tolerate side effects. Expensive; evidence for outcomes is weak. |
Warnings
IV infusions cause rate-dependent flushing and nausea. Human longevity benefits remain unproven. Oral precursors are the better-studied route.